Lakewood-Amedex Biotherapeutics Unveils Promising Results in Diabetic Foot Ulcers Research

Lakewood-Amedex Biotherapeutics Reports Encouraging Results on Nu-3

Lakewood-Amedex Biotherapeutics Inc. recently made headlines with its latest announcement, showcasing positive Minimum Inhibitory Concentration (MIC) data from their lead clinical candidate, Nu-3. This topical formulation, part of the novel Bisphosphocin® class, aims to tackle the growing issue of infections in diabetic foot ulcers (iDFU). These ulcers represent a significant medical challenge, affecting millions globally and often leading to serious complications such as hospitalization or amputation if left untreated.

As part of a Phase 2a clinical trial, Nu-3 is being examined for its efficacy in treating mildly infected diabetic foot ulcers, with topline data expected to be released by the first quarter of 2027. The encouraging MIC data is derived from testing the drug against recent clinical isolates, collected from patients across 14 medical centers in the U.S. within the last three years. These isolates include both resistant and susceptible strains of Staphylococcus aureus (MRSA and MSSA) and Enterococcus faecalis (VRE and VSE).

Dr. Kelvin Cooper, CEO of Lakewood-Amedex, stated, "The positive MIC data in clinical isolates are another encouraging signal supporting continued study of Nu-3 and the Bisphosphocin class." Notably, the study confirmed the drug's potent bactericidal activity against these pathogens, reinforcing its potential as a viable treatment option. Given that close to 50% of diabetic foot ulcers become infected, and up to 20% may involve resistant pathogens, these findings offer a glimmer of hope in addressing the urgent medical need.

A noteworthy aspect of the research was that Nu-3 maintained consistent antibacterial activity against all organisms tested, with MIC values reported to be significantly lower than the planned doses for clinical trials. This suggests a favorable dosing margin and a strong therapeutic window, which is critical given the landscape of rising antibiotic resistance.

Diabetic foot ulcers affect approximately one-third of the 830 million people living with diabetes worldwide, with infections often complicating their condition due to antibiotic-resistant bacteria such as MRSA. Addressing this crisis demands innovative approaches like those being developed by Lakewood-Amedex.

The clinical features of the Bisphosphocin® class and the promising data from Nu-3’s trials demonstrate the potential for a significant breakthrough in managing infections effectively, potentially altering the treatment landscape for diabetic foot ulcers and reducing the burden on healthcare systems.

In addition to the clinical implications, the data shall contribute to the broader dialogue surrounding antibiotic resistance, offering alternative solutions in the face of a post-antibiotic era.

For more information about Lakewood-Amedex Biotherapeutics and their innovative approaches to treating infectious diseases, visit their website Lakewood-Amedex. The company's ongoing clinical development underscores their commitment to combatting the threat posed by antibiotic-resistant pathogens, a pressing healthcare challenge of our time.